Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease
Main Authors: | Bekker, P, Hamilton, G, Johnson, D, Keshav, S, Schall, T |
---|---|
Format: | Conference item |
Published: |
2008
|
Similar Items
-
Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease
by: Bekker, P, et al.
Published: (2008) -
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
by: Bekker, P, et al.
Published: (2007) -
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
by: Bekker, P, et al.
Published: (2009) -
PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
by: Keshav, S, et al.
Published: (2009) -
Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
by: Bekker, P, et al.
Published: (2008)